TFFP: TFF Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TFFP: TFF Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) n/a
Book Value / Share n/a
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share n/a
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) n/a
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets n/a
Assets n/a
Liabilities n/a
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue n/a
Operating Income n/a
Net Income n/a

Cash Flow Statement (mra) ($M)
Cash From Operations n/a
Cash from Investing n/a
Cash from Financing n/a

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-19 13G/A Carlson Capital L P 3.45 -43.11
11-14 13G Armistice Capital, Llc 9.99
05-08 13G Intracoastal Capital, Llc 4.99
02-14 13G/A Lytton Laurence W 0.10 -99.62

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13

(click for more detail)

Similar Companies
AADI – Aadi Bioscience, Inc. ABEO – Abeona Therapeutics Inc.
ABVC – ABVC BioPharma, Inc. ACB – Aurora Cannabis Inc.
ACHV – Achieve Life Sciences, Inc.


Financial data and stock pages provided by
Fintel.io